Zai Lab Shares Are Trading Higher After the Company Presented Data From Its Ongoing Phase 1a/1b Study of ZL-1310 for Previously Treated Extensive-stage Small Cell Lung Cancer at the EORTC-NCI-AACR Symposium 2024.
Zai Lab Shares Are Trading Higher After the Company Presented Data From Its Ongoing Phase 1a/1b Study of ZL-1310 for Previously Treated Extensive-stage Small Cell Lung Cancer at the EORTC-NCI-AACR Symposium 2024.
再鼎醫藥股價上漲,公司在EORTC-新華保險-AACR 2024年研討會上發佈了ZL-1310用於先前接受治療的廣泛期小基站-5g肺癌的Ⅰa/10億研究數據。
Zai Lab Shares Are Trading Higher After the Company Presented Data From Its Ongoing Phase 1a/1b Study of ZL-1310 for Previously Treated Extensive-stage Small Cell Lung Cancer at the EORTC-NCI-AACR Symposium 2024.
再鼎醫藥股價上漲,公司在EORTC-新華保險-AACR 2024年研討會上發佈了ZL-1310用於先前接受治療的廣泛期小基站-5g肺癌的Ⅰa/10億研究數據。